Oncology Medical News about bone metastases; third-generation bisphosphonates; bone pain

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Switching Breast Cancer Patients with Progressive Bone Metastases to Third-Generation Bisphosphonates: Measuring Impact Using the Functional Assessment of Cancer Therapy-Bone Pain
Journal of Pain and Symptom Management, 07/13/09

Broom R et al. - Because bone metastases cause significant pain, the authors developed a questionnaire to evaluate its nature, severity, and impact. This 16-item questionnaire is the Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP). The authors also developed a 13/18-item questionnaire, the Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-Bone Treatment Convenience and Satisfaction Questionnaire (FACIT-TS-BTCSQ), to evaluate patients' expectations and acceptance of bone-specific therapies...There was evidence of construct validity, and known-group validity was supported by score shifts in the anticipated direction. The FACT-BP score reflected clinical change as evidenced by differences in performance status. This cross-sectional anchor-based criterion suggested reasonable clinically important differences. The FACIT-TS-BTCSQ showed good internal consistency reliability for treatment expectation and treatment experience. The FACT-BP scale is meaningful and appears appropriate for broader use. The assessment of satisfaction (FACIT-TS-BTCSQ) raised questions that will require further research.

<< Previous
Combination regimens using doxorubicin and pegylated liposomal...

Next >>
A review of studies mapping (or cross walking) non-preference...